Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19755
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMcKay, Michael J-
dc.contributor.authorTaubman, Kim L-
dc.contributor.authorForoudi, Farshad-
dc.contributor.authorLee, Sze Ting-
dc.contributor.authorScott, Andrew M-
dc.date2018-03-21-
dc.date.accessioned2018-11-04T23:50:36Z-
dc.date.available2018-11-04T23:50:36Z-
dc.date.issued2018-11-15-
dc.identifier.citationInternational Journal of Radiation Oncology, Biology, Physics 2018; 102(4): 783-791en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/19755-
dc.description.abstractAccurate tumor delineation is a priority in radiation therapy (RT). Metabolic imaging has a key and evolving role in target volume selection and delineation. This is especially so for non-small cell lung cancer, squamous cell cancer of the head and neck, and lymphoma, for which positron emission tomography/computed tomography (PET/CT) is complimentary to structural imaging modalities, not only in delineating primary tumors, but also often in revealing previously undiagnosed regional nodal disease. At some sites, PET/CT has been confirmed to enable target size reduction compared with structural imaging alone, with enhanced normal tissue sparing and potentially allowing for dose escalation. These contributions often dramatically affect RT strategies. However, some limitations exist to the use of fluorodeoxyglucose-PET in RT planning, including its relatively poor spatial resolution and partial voluming effects for small tumors. A role is developing for contributions from metabolic imaging to RT planning at other tumor sites and exciting new applications for the use of non-fluorodeoxyglucose metabolic markers for RT planning.en_US
dc.language.isoeng-
dc.titleMolecular Imaging Using PET/CT for Radiation Therapy Planning for Adult Cancers: Current Status and Expanding Applications.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleInternational Journal of Radiation Oncology, Biology, Physicsen_US
dc.identifier.affiliationSchool of Cancer Medicine, Latrobe University, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationMolecular Imaging and Therapyen_US
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen_US
dc.identifier.affiliationFaculty of Medicine, University of Melbourne, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationRadiation Oncologyen_US
dc.identifier.affiliationDepartment of Medical Imaging, St Vincent's Hospital, Fitzroy, Victoria, Australiaen_US
dc.identifier.doi10.1016/j.ijrobp.2018.03.013en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0001-8387-0965en_US
dc.identifier.orcid0000-0001-8641-456Xen_US
dc.identifier.orcid0000-0002-6656-295Xen_US
dc.identifier.pubmedid30353883-
dc.type.austinJournal Article-
dc.type.austinReview-
local.name.researcherForoudi, Farshad
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptRadiation Oncology-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

42
checked on Dec 23, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.